Most Read Articles
Roshini Claire Anthony, 5 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

Stephen Padilla, 6 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
2 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 6 days ago
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.

Emricasan ineffective in NASH patients

01 May 2020

Emricasan appears to be ineffective in improving liver histology in patients with nonalcoholic steatohepatitis (NASH) and may even worsen fibrosis and ballooning, a new trial has shown.

Researchers randomly assigned 318 NASH patients 1:1:1 to receive twice-daily emricasan, at 5 or 50 mg, or matching placebo. The trial lasted for 72 weeks, over which time efficacy was measured as the improvement of at least one NASH Clinical Research Network (CRN) fibrosis stage without further worsening.

NASH resolution was infrequent on both the 5-mg and 50-mg emricasan doses than on placebo (3.7 percent vs 6.6 percent vs 10.5 percent). The same was true for the resolution of fibrosis (3.7 percent vs 0.9 percent vs 4.9 percent, respectively) and disease activity score response (10.3 percent vs 9.4 percent vs 18.1 percent, respectively).

Moreover, more placebo patients saw improvements in fibrosis relative to the 5-mg and 50-mg emricasan dose groups (21.5 percent vs 13.7 percent and 13.4 percent).

On the other hand, emricasan patients showed a significant increase in fibrosis stage from baseline (5-mg: least squares mean [LSM] change, 0.405, 95 percent confidence interval [CI], 0.237–0.572; p=0.004; 50-mg: LSM change, 0.357, 95 percent CI, 0.191–0.523; p=0.013).

The corresponding change in the placebo group was nonsignificant (LSM change, 0.061, 95 percent CI, –0.108 to 0.230). There were also fewer patients in the placebo group who experienced worsening fibrosis than in the 5-mg and 50-mg emricasan groups (20.4 percent vs 41.1 percent and 38.1 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

Stephen Padilla, 6 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
2 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 6 days ago
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.